These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 20860096)

  • 1. [Current usage of molecular targeting drugs].
    Sugio K
    Gan To Kagaku Ryoho; 2010 Aug; 37(8):1459-62. PubMed ID: 20860096
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?
    Dziadziuszko R; Hirsch FR; Varella-Garcia M; Bunn PA
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4409s-4415s. PubMed ID: 16857819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
    Cascone T; Gridelli C; Ciardiello F
    Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular predictors of sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor: confusion or clarity?
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2005 Jul; 7(1):8. PubMed ID: 16098237
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
    Patel JD; Pasche B; Argiris A
    Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
    Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations.
    Jänne PA
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S9-15. PubMed ID: 16459174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies and non-small-cell lung cancer: new developments.
    Gridelli C
    Curr Opin Oncol; 2007 Mar; 19(2):75-7. PubMed ID: 17272976
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
    Raben D; Helfrich B; Bunn PA
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR-directed therapies to treat non-small-cell lung cancer.
    Ho C; Laskin J
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1133-45. PubMed ID: 19572809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing targeted therapies for lung cancer.
    Gandara DR
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):648-9, 690. PubMed ID: 16258461
    [No Abstract]   [Full Text] [Related]  

  • 14. Exploring the future of non-small cell lung cancer treatment.
    Ramalingam S
    Manag Care; 2005 Feb; 14(2 Suppl):9-13; discussion 13-4. PubMed ID: 15776956
    [No Abstract]   [Full Text] [Related]  

  • 15. An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancer.
    Edelman MJ
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S3-8. PubMed ID: 16459173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA; Lynch TJ
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two drugs beat back lung tumors.
    Cancer Discov; 2015 Feb; 5(2):100. PubMed ID: 25656878
    [No Abstract]   [Full Text] [Related]  

  • 18. How should we use bevacizumab in patients with non-small cell lung cancer?
    Kim YH; Mishima M
    J Thorac Oncol; 2011 Dec; 6(12):2145-6. PubMed ID: 22088996
    [No Abstract]   [Full Text] [Related]  

  • 19. Hypoxic active drugs.
    Gatzemeier U
    Suppl Tumori; 2002; 1(4):S15-6. PubMed ID: 12415807
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel agents in the treatment of lung cancer: advances in EGFR-targeted agents. Proceedings of the Third Cambridge Conference. September 23-24, 2005. Cambridge, Massachusetts, USA.
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4365s-4457s. PubMed ID: 16960976
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.